Supernus Pharmaceuticals at the CNS Therapeutics Conference
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), renowned for its commitment to innovating treatments for central nervous system (CNS) disorders, is gearing up for an exciting event. The company has announced its participation in the upcoming Bank of America Securities 2025 CNS Therapeutics Virtual Conference, where Jack A. Khattar, the President and CEO, is set to take the stage. This presentation will demonstrate Supernus's dedication to advancing therapeutic options in the CNS space.
Details of the Virtual Conference Presentation
During the conference, scheduled for December 8, 2025, at 3:20 p.m. ET, Khattar will share insights into the company’s strategic direction and product pipeline. Investors and stakeholders are encouraged to participate and will have the opportunity to arrange meetings with the management team through the conference coordinator.
Engagement with Investors
The conference not only showcases the company's achievements but also allows for direct engagement with investors. A live audio webcast will be available for those who cannot attend in person. This is a golden opportunity for current and potential investors to gain a deeper understanding of Supernus's vision and market positioning.
About Supernus Pharmaceuticals
Established to focus on the development and commercialization of products targeting CNS diseases, Supernus has developed a diverse portfolio that includes treatments for various conditions such as attention-deficit hyperactivity disorder (ADHD), Parkinson's disease, and epilepsy. The company is committed to addressing the needs of patients with CNS disorders, making significant strides in the biopharmaceutical industry.
Diverse Portfolio of Treatments
Supernus Pharmaceuticals offers an impressive range of FDA-approved therapies aimed at improving patient outcomes. Their products also target conditions like dyskinesia in Parkinson's patients, chronic sialorrhea, and postpartum depression. As they expand their portfolio, the focus remains on innovating treatment strategies that effectively address these complex conditions.
Future Outlook and Development
Looking ahead, Supernus Pharmaceuticals is dedicated to innovating new therapies. The company is actively involved in clinical trials to broaden its range of product candidates. Their commitment to research in neuroscience plays a vital role in developing transformative therapies for patients suffering from various CNS disorders.
Contacts and Investor Relations
For anyone seeking to learn more about Supernus Pharmaceuticals, detailed information can be found on their official website. Furthermore, company representatives are accessible for inquiries, with Jack Khattar and Timothy Dec leading the charge in providing crucial insights about the company’s direction.
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Frequently Asked Questions
What is the focus of Supernus Pharmaceuticals?
Supernus Pharmaceuticals focuses on developing and commercializing therapies for the treatment of central nervous system diseases.
Who will be presenting at the conference?
Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will be presenting at the conference.
When is the CNS Therapeutics Virtual Conference?
The conference is scheduled for December 8, 2025.
How can investors engage with Supernus management?
Investors can arrange meetings through the Bank of America conference coordinator during the event.
Where can I find more information about Supernus Pharmaceuticals?
Further details about Supernus Pharmaceuticals and its product pipeline can be found on their official website, www.supernus.com.
